𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Systemic therapy in disseminated melanoma

✍ Scribed by Ph. Rümke

Book ID
104594143
Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
878 KB
Volume
8
Category
Article
ISSN
8756-0437

No coin nor oath required. For personal study only.

✦ Synopsis

There is no standard treatment for advanced melanoma. As long as metastases are satellites or in-transit metastases localized in a leg or arm, the prospects for curative treatment by isolation perfusion are good. But as soon as metastases have spread via the circulation, curative treatment with cytotoxic agents becomes virtually impossible. When the tumor burden is not too extensive, however, palliative treatment can be of clinical value. Some combinations of cytotoxic agents or combinations of biologic response modifiers have been shown to induce worthwhile remissions. Toxicity remains a problem, however. The advantages of the newer immunological approaches, especially with interleukin-2 (IL-2) and T-cell lymphocytes, is that treatment for a short period may result in good remissions at an early stage. Much clinical research is still needed to improve these costly approaches.

📜 SIMILAR VOLUMES

A Phase II trial of vinorelbine tartrate
A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy : A Southwest Oncology Group study
✍ Robert P. Whitehead; James Moon; S. Spence McCachren; Evan M. Hersh; Wolfram E. 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 3 views

## Abstract ## BACKGROUND Single‐agent chemotherapy with dacarbazine continues to be the standard of care for the treatment of metastatic melanoma. However, there is a large population of patients who have failed first‐line therapy and might benefit from additional treatment. In the current study,

Systemic therapy in melanoma
Systemic therapy in melanoma
✍ Faith E. Nathan; Michael J. Mastrangelo 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

The patient with surgically incurable melanoma presents a difficult problem for the medical oncologist. Single chemotherapeutic agents at conventional doses produce bona fide but infrequent remissions. The most active single agent for the treatment of metastatic melanoma is dacarbazine (DTIC). Until